-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Pharmaceutical Network October 20, recently, NMPA official website data show that Chengdu Yuandong Biopharmaceutical's Grombromin ammonium injection class 3 imitation listing application has entered the "in the approval" state.
October 10, 2020, Hengrui Pharmaceuticals announced that it had won the "first imitation and first evaluation" of the Glon ammonium bromide injection, which cost about 14.89 million yuan to invest in research and development.
figure 1: Chengdu Yuandong Biopharmaceutical Grombromide injection registration source: NMPA official mesh lon bromine is a quarterly ammonium anticholinelic drug, with inhibition of gastric fluid secretion and regulation of gastrointestinal peristaltic action, suitable for stomach and tidal ulcers, chronic gastritis, gastric acid secretion, etc. , static injection or creatine can be used for pre-anesthetic administration.
Figure 2: Declared Glon ammonium bromide injection imitation listed enterprises Source: Minet MED2.0 China Drug Review Database October 10, 2020, Hengrui announced that the company's Grombromide injection was approved for the market, for the product "first Imitation and the first evaluation of "enterprises, the current Chengdu Yuandong Biological 3 types of imitation listing applications have also entered the "in the approval" state, in addition, Guangdong Jiabo Pharmaceuticals, Guangdong Zhongrun Pharmaceutical Research and Development, Guangdong Xingyu Pharmaceuticals listing applications are in the review and approval, Jiangsu Coastal Pharmaceuticals listing applications have been approved clinically.
table 1: 2018 to date Chengdu Yuandong Biopharmaceutical approved listed product sources: Minenet MED2.0 China Drug Review Database Minet data show that so far in 2018, Chengdu Yuandong Biopharmaceutical approved listed products have 5, which took the first domestic imitation of ibuprofen injection, as well as take the second domestic good results relying on the kaoxi tablets, if this Glon ammonium bromide injection successfully approved, will become the second domestic product.
source: NMPA official website, MiNet database.
